Literature DB >> 14642624

In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy.

Ingrid J Hickman1, Elizabeth E Powell, Johannes B Prins, Andrew D Clouston, Susan Ash, David M Purdie, Julie R Jonsson.   

Abstract

BACKGROUND/AIMS: Host factors such as increased body mass index (BMI) and genotype-specific viral factors contribute to the development of steatosis in patients with chronic hepatitis C (HCV). We hypothesized that host metabolic factors associated with increased BMI may play a role in disease progression.
METHODS: Fasting serum was collected from 160 patients with chronic HCV at the time of liver biopsy and 45 age, gender and BMI matched controls, and assessed for levels of insulin, c-peptide and leptin.
RESULTS: Patients with viral genotype 3 had more severe steatosis (P=0.0001) and developed stages 1 and 2 fibrosis at a younger age (P<0.05) than patients with genotype 1. For both genotypes, overweight patients had significantly more steatosis and increased insulin and leptin levels. In contrast to lean patients, there was a statistically significant increase in circulating insulin levels with increasing fibrosis in overweight patients with chronic HCV (P=0.03). Following multivariate analysis, insulin was independently associated with fibrosis (P=0.046) but not inflammation (P=0.83). There was no association between serum leptin levels and stage of fibrosis.
CONCLUSIONS: Increasing circulating insulin levels may be a factor responsible for the association between BMI and fibrosis in patients with HCV, irrespective of viral genotype.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14642624     DOI: 10.1016/s0168-8278(03)00463-x

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  39 in total

1.  Hepatitis C virus and insulin resistance/diabetes mellitus.

Authors:  Dawn M Torres; Stephen A Harrison
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-08

2.  Predicting the probable outcome of treatment in HCV patients.

Authors:  Udayakumar Navaneethan; Nyingi Kemmer; Guy W Neff
Journal:  Therap Adv Gastroenterol       Date:  2009-09       Impact factor: 4.409

Review 3.  Steatosis in chronic hepatitis C: why does it really matter?

Authors:  T Asselah; L Rubbia-Brandt; P Marcellin; F Negro
Journal:  Gut       Date:  2006-01       Impact factor: 23.059

4.  Acute and chronic immune biomarker changes during interferon/ribavirin treatment in HIV/HCV co-infected patients.

Authors:  M K Jain; B Adams-Huet; D Terekhova; L E Kushner; R Bedimo; X Li; M Holodniy
Journal:  J Viral Hepat       Date:  2014-02-09       Impact factor: 3.728

5.  Adipokines levels are associated with the severity of liver disease in patients with alcoholic cirrhosis.

Authors:  Maria Kalafateli; Christos Triantos; Emmanuel Tsochatzis; Marina Michalaki; Efstratios Koutroumpakis; Konstantinos Thomopoulos; Venetsanea Kyriazopoulou; Eleni Jelastopulu; Andrew Burroughs; Chryssoula Lambropoulou-Karatza; Vasiliki Nikolopoulou
Journal:  World J Gastroenterol       Date:  2015-03-14       Impact factor: 5.742

Review 6.  The role of lifestyle changes in the management of chronic liver disease.

Authors:  Valerio Nobili; Christine Carter-Kent; Ariel E Feldstein
Journal:  BMC Med       Date:  2011-06-06       Impact factor: 8.775

7.  Evolution of interferon-based therapy for chronic hepatitis C.

Authors:  Chun-Hao Chen; Ming-Lung Yu
Journal:  Hepat Res Treat       Date:  2010-10-10

Review 8.  Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen.

Authors:  Amedeo Lonardo; Luigi Elio Adinolfi; Luciano Restivo; Stefano Ballestri; Dante Romagnoli; Enrica Baldelli; Fabio Nascimbeni; Paola Loria
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

Review 9.  A growing burden: the pathogenesis, investigation and management of non-alcoholic fatty liver disease.

Authors:  P Riley; J O'Donohue; M Crook
Journal:  J Clin Pathol       Date:  2007-05-04       Impact factor: 3.411

10.  Peroxisome proliferator-activated receptors and hepatitis C virus-induced insulin resistance.

Authors:  Francesco Negro
Journal:  PPAR Res       Date:  2009-01-06       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.